DNA mapping for cancer patients

 
DNA The human genome contains three billion pairs of code

Up to 100,000 patients with cancer and rare diseases in England are to have their entire genetic code sequenced.

The Prime Minister will announce £100m has been set aside for the project over the next three to five years.

The aim is to give doctors a better understanding of patients' genetic make-up, condition and treatment needs, and help develop new cancer treatments.

One human genome contains three billion base pairs - the building blocks of DNA.

Sequencing the code produces a huge amount of data. Although the price is falling fast, it currently costs £5,000 to £10,000 - which explains why no country in the world has embarked on mass DNA mapping on this scale.

When it will start - who will do the genome sequencing and analysis - has not been worked out - nor which patients will be eligible for the voluntary testing.

But the hope is by comparing genetic profiles of huge numbers of patients, it will allow scientists to understand why some do far better than others - and help in the quest for new treatments.

Privacy campaigners are concern such a move could allow personal data to be passed on to private companies, such as insurance companies.

Dr Kat Arney from Cancer Research UK: ''There could be very big benefits for cancer patients in the future''

But ministers insist the project is for medical research alone.

For existing patients, DNA mapping may lead to better targeting of medicines.

The power of this type of genetic analysis was demonstrated earlier this year when a study of 2,000 breast cancers showed the cancer should be thought of as 10 completely separate diseases.

Personalised therapies

There are already a handful of targeted treatments - for breast, lung, bowel and blood cancers - where tests for a single gene can reveal whether a patient is likely to respond.

For example, breast cancer patients are tested to see if their tumour is positive for 'Her2', a protein that can accelerate the growth of malignant cells. If so they can benefit from Herceptin, a drug which works on patients with high levels of the Her2 protein.

Whole genome mapping may yield more of these personalised therapies.

Speaking ahead of the announcement David Cameron said: "By unlocking the power of DNA data, the NHS will lead the global race for better tests, better drugs and above all better care."

The chief medical officer for England, Prof Dame Sally Davies, said: "Single gene testing is already available across the NHS ranging from diagnosing cancers to assessing patients' risk of suffering side effects from treatment.

"At the moment, these tests focus on diseases caused by changes in a single gene. This funding opens up the possibility of being able to look at the three billion DNA pieces in each of us so we can get a greater understanding of the complex relationship between our genes and lifestyle."

Stratified medicine

  • Cancer Research UK launched it 'stratified medicine' project last year. It aims to group, or 'stratify' patients into those who will respond best to particular treatments. DNA samples of 9,000 patients with breast, bowel, prostate, lung and ovarian cancer, and melanoma are being collected at seven centres across the UK. The genetic make-up of the cancer will be analysed and the key mutations noted. The information will be stored as a guide to help future research.

There are a number of existing projects seeking to improve understanding of the genetics of cancer, such as Cancer Research UK's 'stratified medicine' programme.

The UK is part of the International Cancer Genome Consortium which is planning to sequence 50 different cancers and catalogue their different mutations.

There are more than 200 types of cancer - it is a complex and highly resistant disease - the talk among specialists is less of cures and more of improved long-term outcomes.

So most of the benefits from these ambitious projects are likely to be among the next generation of cancer patients.

 
Fergus Walsh Article written by Fergus Walsh Fergus Walsh Medical correspondent

Superbugs to kill 'more than cancer' by 2050

Drug resistant infections will kill an extra 10 million people a year worldwide by 2050 unless action is taken, a study says.

Read full article

More on This Story

Related Stories

Comments

This entry is now closed for comments

Jump to comments pagination
 
  • rate this
    +1

    Comment number 224.

    numbers should never be an issue when it comes to research, there is not that many surviving cancer patients, studies have included a lot more for the uptake.This is a well established subject, lets just let the experts get on with carrying it out.

  • rate this
    +1

    Comment number 223.

    @221: For many projects, the research team might be able to handle analysis (and we generally do). For a project of this magnitude, it would need dedicated bioinformaticians. With the technologies used for modern high-throughput sequencing, even a single genome generated by 454/Illumina is far more complex than those generated for the human genome project because of the depth of coverage.

  • rate this
    +1

    Comment number 222.

    we have to trust the expertise of the researchers, thats all you can ask as a cancer patient. I have seen some great research into all aspects of care, i have no reason to not be excited about this new research. If it saves my children, and their children from going through what i have it will certainly be money well spent. If it stops some nvasive treatment it will be even better.

  • rate this
    +1

    Comment number 221.

    At the end of the day, all i have is hope that one day their will be a cure, its quite often the research term that conduct their own evaluation, and that is the norm, they more often then not do their own analysis, i can make sense of this, but maybe that is because i come from a research background, this is not a very expensive piece of research, but it would have good outcomes for patients.

  • rate this
    +1

    Comment number 220.

    I'm more concerned about who is going to analyse all the sequencing data that comes from this project. There is currently a severe national deficit in experienced high-level bioinformaticians and computational biologists, with only limited funding going into training new ones. Just having the data (millions of bases per genome, thousands of genomes) is not enough - you need to make sense of it!

 

Comments 5 of 224

 

Features

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.